Seattle biotech had a little something for everybody this past week. There was drama (Dendreon), politics (Life Sciences Discovery Fund getting whacked), a scientist’s life story (David Baker), and young competitors vying to make the world a better place (UW Environmental Innovation Challenge). -Dendreon (NASDAQ: DNDN), the Seattle developer of an immune-stimulating therapy for prostate cancer, …
Read the rest here:
Dendreon Saga Nears Climax, Gregoire Biotech Fund in Jeopardy, UW’s Biofuel Futurist, & More Seattle-Area Life … (Seattle Post-Intelligencer)
